Phase 1 Leukaemia Clinical Trials
33 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 33 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1Phase 2
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Relapsed or Resistant Acute Leukaemias
Lin BioScience, Inc90 enrolled17 locationsNCT05756322
Recruiting
Phase 1Phase 2
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Acute Myeloblastic LeukaemiaLeukemia, T-Cell
Gyala Therapeutics33 enrolled2 locationsNCT07471789
Recruiting
Phase 1
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital27 enrolled4 locationsNCT06326021
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 1
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 1Phase 2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled36 locationsNCT05658640
Recruiting
Phase 1Phase 2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05745714
Recruiting
Phase 1Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Phase 1Phase 2
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukaemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20 enrolled1 locationNCT07036250
Not Yet Recruiting
Phase 1
Microbiome and Fibre Supplementation in Chimeric Antigen Receptor T cell Therapy - phase I clinical trial of safety and feasibility of oral fibre supplementation in CAR T
LymphomaMyelomaAcute Leukaemia
Metro North Hospital and Health Service30 enrolled1 locationACTRN12625000056493
Terminated
Phase 1
A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome
Refractory/Relapsed (R/R) acute myeloid leukaemia (AML)High risk myelodysplastic syndrome (MDS)Extremely high risk myelodysplastic syndrome (MDS)+1 more
LAVA Therapeutics N.V.50 enrolled4 locationsACTRN12624001214527
Recruiting
Phase 1
An Exploratory Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers
Acute Myeloid Leukaemia (AML)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)88 enrolled1 locationACTRN12624000180516
Completed
Phase 1
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part B
Parkinson's Disease (PD)Chronic Myeloid Leukaemia (CML)
Enliven Therapeutics, Inc.15 enrolled1 locationACTRN12624000116527
Completed
Phase 1
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part A
Parkinson's Disease (PD)Chronic Myeloid Leukaemia (CML)
Enliven Therapeutics, Inc.15 enrolled1 locationACTRN12624000115538
Recruiting
Phase 1
Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies.
Acute leukaemia (myeloid and/or lymphoid, or biphenotypic)
Melbourne Health18 enrolled2 locationsACTRN12622000308796
Recruiting
Phase 1
CAR T cell therapy for CD19-positive cancer - phase I clinical trial
B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.
Metro North Hospital and Health Service31 enrolled1 locationACTRN12621000762853